Clinical Trials Logo

Eczema clinical trials

View clinical trials related to Eczema.

Filter by:

NCT ID: NCT05765461 Recruiting - Atopic Dermatitis Clinical Trials

Effect of Lipikar Baume AP+M on Quality of Life and Pain of Adults With Dryness or Severe Xerosis

Start date: September 1, 2020
Phase:
Study type: Observational

This study aims at evaluating the effect of a topical product on the improvement of quality of life and pain of patients suffering from atopic dermatitis or other skin diseases with dryness or severe xerosis. Patients aged 16 years and over are asked to apply the product once or twice a day for 2 months. They may be prescribed a corticosteroid upon decision of the dermatologist.

NCT ID: NCT05758532 Recruiting - Allergy Clinical Trials

Non-specific Effects of a Modified Measles Vaccination Schedule to Prevent Allergy and Unrelated Infection in Children

NEMAU
Start date: March 17, 2023
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to evaluate the off-target/non-specific effects of the measles-mumps-rubella (MMR) vaccine in children.

NCT ID: NCT05735483 Recruiting - Atopic Dermatitis Clinical Trials

A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

ADorable-2
Start date: March 9, 2023
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to <18 years of age with moderate-to-severe atopic dermatitis

NCT ID: NCT05717920 Recruiting - Atopic Dermatitis Clinical Trials

A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)

Start date: February 15, 2023
Phase: Phase 2
Study type: Interventional

A Phase 2, multicenter, adaptive 2-part clinical trial designed to evaluate the safety and efficacy of ADX-629 alone and in combination with standard-of-care in adults with atopic dermatitis.

NCT ID: NCT05715320 Recruiting - Atopic Dermatitis Clinical Trials

Study of CM310 Injection in Subjects With Moderate-to-Severe Atopic Dermatitis

Start date: March 10, 2023
Phase: Phase 2
Study type: Interventional

This study is a multi-center, randomized, double-blind, parallel controlled phase 2 study, aimed at evaluating the efficacy and safety of CM310 in the treatment of patients with moderate-to-severe atopic dermatitis, and observing Pharmacokinetics characteristics, Pharmacodynamics effects and immunogenicity.

NCT ID: NCT05704738 Recruiting - Atopic Dermatitis Clinical Trials

A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD)

ROCKET-ASTRO
Start date: April 20, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent subjects.

NCT ID: NCT05704205 Recruiting - Atopic Dermatitis Clinical Trials

The UPDATE Trial (Uvb Phototherapy in Dermatology for ATopic Eczema)

UPDATE
Start date: February 22, 2023
Phase: N/A
Study type: Interventional

The goal of this randomized controlled trial is to study the (cost)effectiveness of NB-UVB phototherapy in patients with atopic eczema/atopic dermatitis. Half of the participants will undergo a course of NB-UVB phototherapy of 8-16 weeks and apply optimal topical therapy (OTT) for a minimum of 3 months. Researchers will compare the outcomes of this group with the other half of participants that apply OTT only.

NCT ID: NCT05702268 Recruiting - Clinical trials for Moderate to Severe Atopic Dermatitis

Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis

Start date: March 18, 2023
Phase: Phase 2
Study type: Interventional

The investigator, the subject, and the sponsor's project team will remain blind throughout the study. Subjects will be randomly assigned to one of the three treatment groups at a ratio of 1:1:1 to be given the drug once a day for 4 weeks.

NCT ID: NCT05696392 Recruiting - Atopic Dermatitis Clinical Trials

The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.

MORPHEUS
Start date: March 16, 2023
Phase: Phase 4
Study type: Interventional

The purpose of the study is to evaluate the effect of ruxolitinib cream on sleep disturbances with participants with Atopic Dermatitis.

NCT ID: NCT05694884 Recruiting - Atopic Dermatitis Clinical Trials

Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab

Start date: December 21, 2022
Phase: Phase 2
Study type: Interventional

Multicenter, randomized, double-blind, placebo-controlled, parallel arm clinical study designed to evaluate the efficacy and safety of eblasakimab in participants with moderate-to-severe atopic dermatitis (AD) previously treated with dupilumab.The study consists of a 16-week treatment period and an 8-week follow-up period up to Week 24. Eligible participants will be randomized into one of the 2 treatment arms.